- For Print
- June 3, 2024
Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that TIME has selected Eisai as one of the TIME100 Most Influential Companies of 2024.
TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. To assemble the list, TIME solicited nominations across sectors, and polled its global network of contributors and correspondents, as well as outside experts. Then TIME editors evaluated each company based on key factors, including impact, innovation, ambition, and success. Eisai is recognized in the “Pioneers” category for its human health care (hhc) concept of prioritizing patient needs and the development of our Alzheimer’s disease treatment LEQEMBI® (lecanemab). (For more information, please visit )
LEQEMBI is the first and only treatment approved in Japan, the United States, China, and South Korea shown to reduce the rate of disease progression and to slow cognitive and functional decline, that acts on the underlying pathology of AD.
AD is a progressive, fatal disease, and a global healthcare issue that greatly impacts not only the people living with the disease, but also their loved ones, care partners and society. Based on our corporate concept of "human health care (hhc)," we have taken on the challenge of this difficult issue through our nearly 40 years of drug discovery activities in the field of dementia, while spending time with patients and their families. We will deliver LEQEMBI to the people with early AD who need it and their families, and aim to continue creating impact on global issues surrounding dementia.
Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen Inc. (U.S.) co-commercializing and co-promoting the product and Eisai having final decision-making authority.
Please see full , including Boxed WARNING in the United States.
&苍产蝉辫;銆赌銆赌
銆赌
MEDIA CONTACTS:
爱豆传媒.
Public Relations Department
TEL: +81 (0)3-3817-5120